BioSpace News Archive

Oncopeptides AB ‘s Annual General Meeting 2020 was held , at Tändstickspalatset in Stockholm.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the second quarter of 2020.

Indus Holdings, Inc. (“Indus”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated cannabis company, will release its financial results for the first quarter 2020 (ended March 31, 2020) after the market closes on Thursday, May 28.

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology.

Stryker announced that it has priced the following senior notes: $650 million aggregate principal amount of the Company’s 1.150% Notes due 2025, $1 billion aggregate principal amount of the Company’s 1.950% Notes due 2030, and $650 million aggregate principal amount of the Company’s 2.900% Notes due 2050.

Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to shareholders updating them on the Company’s execution against the key strategic actions committed to in September 2019 to position Harvard Bioscience for long-term profitable growth.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

DaVita Inc. announced the pricing of its previously announced private offering of $1.75 billion aggregate principal amount of senior notes due 2030.

LAIX Inc. (“LAIX” or the “Company”) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced its unaudited financial results for the first quarter ended March 31, 2020.